Return to ads
All categories


Posted by
Posting ads for 49 years
Following the announcement that the FDA approved the first active immune-booster Provenge, the stocks of Dendreon (DNDN) skyrocketed until they reached a halt at $45.50. Well now, we have news that share trading has DNDN increased to $53.50, another big jump."The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available," Karen Midthun, acting head of the FDA biologics center, said in a statement.DNDN is right now a hot share in the Internet share trading sites. We'll keep a watch on the evolution of this and will bring you more updates.Related posts:Dendreon Prostate Cancer Treatment Gets Approved by FDA, Share Dealing RisesGoldman Sachs Trading Responds to SECImpressive Q1 Intel Earnings Interest Among Online Stock Market Trading SitesFabrice Tourre, From Goldman Sachs Trading Carged With FraudKaren Sypher PICSTags: Dendreon, DNDN, Provenge, Share Trading ...

Reply to this ad
Recently viewed ads
Saved ads
Please log in to browse your saved adverts or sign up if you don't have an account yet.
Popular Stuff